<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481116</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-875_304</org_study_id>
    <secondary_id>2011-001731-24</secondary_id>
    <secondary_id>U1111-1124-2296</secondary_id>
    <secondary_id>TAK-875_304CTIL</secondary_id>
    <secondary_id>DOH-27-0512-3913</secondary_id>
    <secondary_id>11-057</secondary_id>
    <secondary_id>NMRR-11-882-10318</secondary_id>
    <secondary_id>HKCTR-1616</secondary_id>
    <secondary_id>262</secondary_id>
    <secondary_id>12/WA/0245</secondary_id>
    <nct_id>NCT01481116</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination With Metformin in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of TAK-875, once daily
      (QD), plus metformin compared to glimepiride plus metformin in participants with type 2
      diabetes mellitus (T2DM).

      The purpose of this study is to determine the efficacy and safety of TAK-875, once daily
      (QD), plus metformin compared to glimepiride plus metformin in participants with type 2
      diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) has increased dramatically throughout the world over the past
      decades despite the availability of several different treatment options. Current
      pharmacologic treatments include insulin, thiazolidinediones, sulfonylureas, metformin,
      dipeptidyl-peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) mimetics. A
      number of these treatments are associated with clinically important side effects such as low
      blood sugar (hypoglycemia), weight gainflud retention, exaggeration of pre-existent heart
      failure, and gastrointestinal side effects. These side effects and the disadvantages
      associated with many of the currently available antidiabetic agents can reduce compliance and
      limit their long-term use.

      Insulin is a hormone that is produced by the body to regulate blood sugar (glucose). In
      individuals with T2DM, the insulin produced by the body does not effectively control the
      amount of sugar in the bloodstream. If not properly managed, T2DM may cause elevated blood
      sugar levels (hyperglycemia) and ultimately result in serious health problems.

      In response to this problem, Takeda is developing TAK-875 (an investigational drug) as an
      addition to diet and exercise to improve blood sugar control in patients with T2DM. TAK-875
      may affect the production of insulin and may improve how the body uses the sugar in the
      blood.

      The aim of this study is to find out if TAK-875, when taken for approximately 2 years in
      combination with current diabetes medicine (called metformin), is safe and effective at
      helping people with T2DM control their high blood sugar when compared to glimepiride (a type
      of medication called a sulfonylurea). The study is being done to find out if the combination
      of TAK-875 plus metformin works as well as the combination of glimepiride plus metformin.

      Approximately 2430 patients worldwide aged 18 or over with T2DM, will take part in this study
      and will be involved in the study for up to 110 or 120 weeks.

      TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to
      diet and exercise to improve glycemic control in participants with T2DM.

      This study will investigate TAK-875 in participants with type 2 diabetes mellitus whose blood
      sugar level is inadequately controlled with metformin monotherapy.

      Due to potential concerns about liver safety, on balance, the benefits of treating patients
      with fasiglifam (TAK-875) do not outweigh the potential risks.

      For this reason, Takeda has decided voluntarily to terminate the development activities for
      fasiglifam.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to potential concerns about liver safety (See Detailed Description)
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Weeks 78 and 104</measure>
    <time_frame>Baseline and Weeks 78 and 104</time_frame>
    <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) to be collected at Weeks 78 and 104 relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypoglycemia</measure>
    <time_frame>Day 1 up to Weeks 78 and 104</time_frame>
    <description>Participants were provided diaries to document any hypoglycemic events that occurred between study visits. Any experience of hypoglycemic signs and symptoms (regardless of the blood glucose value by glucometer) or had a blood glucose value less than or equal to (&lt;=) 70 milligram per deciliter (mg/dL) (3.9 millimole per liter (mmol/L) by glucometer (regardless of symptoms) were to be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Weeks 78 and 104</measure>
    <time_frame>Baseline and Weeks 78 and 104</time_frame>
    <description>The change between the body weight to be collected at Weeks 78 and 104 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Weeks 26 and 52</measure>
    <time_frame>Baseline and Weeks 26 and 52</time_frame>
    <description>The change in the value of HbA1c collected at Weeks 26 and 52 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HbA1c &lt;7%</measure>
    <time_frame>Weeks 26, 52, 78 and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HbA1c &lt;7% for Participants Who Did Not Report Hypoglycemia</measure>
    <time_frame>Weeks 26, 52, 78 and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104</measure>
    <time_frame>Baseline and Weeks 26, 52, 78 and 104</time_frame>
    <description>The change between the fasting plasma glucose value to be collected at Weeks 26, 52, 78 and 104 relative to baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2454</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>TAK-875 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-875 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride 1-2 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-875</intervention_name>
    <description>TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.</description>
    <arm_group_label>TAK-875 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-875</intervention_name>
    <description>TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.</description>
    <arm_group_label>TAK-875 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.</description>
    <arm_group_label>Glimepiride 1-2 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. The participant is male or female and 18 years of age or older with a historical
             diagnosis of T2DM.

          4. The participant meets one of the following criteria:

               1. The participant has an HbA1c level ≥7.0 and &lt;10.0%, and has been on a stable
                  daily dose of ≥1500 mg (or documented MTD) of metformin for at least 2 months
                  prior to Screening. This participant will immediately enter the Placebo Run-in
                  Period, or;

               2. The participant has an HbA1c level ≥ 7.5 and &lt;10.5%, and has been on a stable
                  daily dose of &lt;1500 mg of metformin without documented MTD for at least 2 months
                  prior to Screening. After completing the Screening Visit, this participant will
                  have their metformin dose immediately increased to ≥1500 mg (or MTD) for an
                  8-week Titration Period. Following this 8-week period, the participant must
                  qualify for entry into the Placebo Run-in Period by completing the Week -3
                  procedures and having an HbA1c concentration ≥7.0 and &lt;10.0%.

          5. The participant has had no treatment with antidiabetic agents other than metformin
             within 2 months prior to Screening (Exception: if a participant has received other
             antidiabetic therapy for ≤7 days within the 2 months prior to Screening).

          6. The participant has a body mass index (BMI) of ≤45 kg/m2 at Screening.

          7. Participants regularly using other, non-excluded medications, must be on a stable dose
             for at least 4 weeks prior to Screening. However, PRN (as needed) use of prescription
             or over-the-counter medications is allowed at the discretion of the investigator.

          8. The participant is able and willing to monitor glucose with a home glucose monitor and
             consistently record his or her own blood glucose concentrations and complete
             participant diaries.

        Additional Inclusion Criteria Prior to Randomization

          1. The participant has an HbA1c concentration ≥7.0% and &lt;10.0%, and a FPG ≤270 mg/dL
             (15.0 mmol/L) at the Week -1 Visit. (If the subject does not qualify for randomization
             based on these criteria, the assessment may be repeated weekly, for a maximum of 2
             additional weeks).

          2. The participant's compliance with the single-blind study medication during the Placebo
             Run-in Period is at least 75% and does not exceed 125% based on tablet/capsule counts
             performed by the study staff.

          3. A female participant of childbearing potential must have a negative urine hCG
             pregnancy test at Baseline (Day 1) prior to Randomization and prior to administration
             of the first dose of double-blind study medication.

        Exclusion Criteria:

          1. The participant has received any investigational compound within 30 days prior to
             Screening or has received an investigational antidiabetic drug within the 3 months
             prior to Screening.

          2. The participant has been randomized into a previous TAK-875 study

          3. The participant is an immediate family member, study site employee, or is in a
             dependant relationship with a study site employee who is involved in conduct of this
             study (e.g., spouse, parent, child, sibling) or may consent under duress.

          4. The participant donated or received any blood products within 12 weeks prior to
             Screening or is planning to donate blood during the study.

          5. The participant has a hemoglobin ≤12 g/dL (≤120 gm/L) for males and ≤10 g/dL (≤100
             gm/L) for females at Screening.

          6. The participant has a systolic blood pressure ≥160 mm Hg or diastolic pressure ≥95 mm
             Hg at Screening (If the participant meets this exclusion criterion, the assessment may
             be repeated once at least 30 minutes after the initial measurement).

          7. The participant has history of cancer that has been in remission for &lt;5 years prior to
             Screening. A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the
             skin is allowed.

          8. The participant has alanine aminotransferase (ALT) and/or aspartate aminotransferase
             (AST) levels &gt;2.0x upper limit of normal (ULN) at Screening.

          9. The participant has a total bilirubin level greater than the ULN at Screening.
             Exception: if a participant has documented Gilbert's Syndrome the participant will be
             allowed with an elevated bilirubin level per the investigator's discretion.

         10. The participant has a serum creatinine ≥1.5 mg/dL(males) and ≥1.4 mg/dL(females)
             and/or estimated glomerular filtration rate (GFR) &lt;60 mL/min/1.73m2 at Screening.

         11. The participant has uncontrolled thyroid disease.

         12. The participant has a history of laser treatment for proliferative diabetic
             retinopathy within 6 months prior to Screening.

         13. The participant has had gastric banding, or gastric bypass surgery within one year
             prior to Screening.

         14. The participant has a known history of infection with human immunodeficiency virus
             (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).

         15. The participant had coronary angioplasty, coronary stent placement, coronary bypass
             surgery, myocardial infarction, unstable angina pectoris, clinically significant
             abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic
             attack within 3 months prior to or at Screening.

         16. The participant has a history of hypersensitivity, allergies, or has had an
             anaphylactic reaction(s) to any component of TAK-875, metformin, or glimepiride.

         17. The participant has a history of drug abuse (defined as illicit drug use) or a history
             of alcohol abuse within 2 years prior to Screening.

         18. The participant received excluded medications prior to Screening or is expected to
             receive excluded medication.

         19. If female, the participant is pregnant (confirmed by laboratory testing, i.e.,
             serum/urine human chorionic gonadotropin (hCG), in females of childbearing potential)
             or lactating or intending to become pregnant before, during, or within 1 month after
             participating in this study; or intending to donate ova during such time period.

         20. The participant is unable to understand verbal or written English or any other
             language for which a certified translation of the approved informed consent is
             available.

         21. The participant has any other physical or psychiatric disease or condition that in the
             judgment of the investigator may affect life expectancy or may make it difficult to
             successfully manage and follow the participant according to the protocol.

        Additional Exclusion Criteria Prior to Randomization

          1. The participant has received excluded medications listed in the protocol during the
             Placebo Run-in Period (topical and inhaled corticosteroids are allowed).

          2. The participant has a systolic blood pressure ≥160 mm Hg or diastolic blood pressure
             ≥95 mm Hg at Baseline (Day 1) (If the subject meets this exclusion criterion, the
             assessment may be repeated once at least 30 minutes after the initial measurement and
             decision will be made based on the second measurement).

          3. The participant has a serum creatinine ≥1.5 mg/dL(≥133µmol/L) [males] and ≥1.4 mg/dL
             (≥124 µmol/L) [females] and/or estimated glomerular filtration rate (GFR) &lt;60
             mL/min/1.73m2 at Visit 3 (Schedule B subjects only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Ciudad Autonoma Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mosman</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woy Woy</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canberra</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gabrovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ville Saint-Laurent</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chocen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marianske Lazne</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava - Moravska Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava - Vitkovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4 - Krc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paide</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rakvere</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saku</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Võru</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Givataim</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raanana</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rechovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rishon le Zion</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limbazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiping, Perak</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiping</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Putrajaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lipa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarlac</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taytay</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamieniec Zabkowicki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leczyca</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulawy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kempton Park</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middelburg</city>
        <state>Mpumalanga</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chia-Yi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mykolayiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheadle</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <state>East Riding of Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bexhill on Sea</city>
        <state>East Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Watford</city>
        <state>Hertfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornton-Cleveleys</city>
        <state>Lancashire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swansea</city>
        <state>South Glamorgan</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <results_first_submitted>July 24, 2015</results_first_submitted>
  <results_first_submitted_qc>April 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2016</results_first_posted>
  <last_update_submitted>April 24, 2016</last_update_submitted>
  <last_update_submitted_qc>April 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part at 291 sites in Argentina, Australia, Bulgaria, Canada, Colombia, Czech Republic, Estonia, Hong Kong, Israel, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, the Russian Federation, South Africa, Taiwan, Ukraine, the United Kingdom and the United States from 06 November 2011 to 24 April 2014.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of type 2 diabetes mellitus who were inadequately controlled while receiving metformin alone were enrolled in 1 of 3 treatment groups as follows: glimepiride; TAK-875 25 milligram (mg); TAK-875 50 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glimepiride</title>
          <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
        </group>
        <group group_id="P2">
          <title>TAK-875 25 mg</title>
          <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>TAK-875 50 mg</title>
          <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="824"/>
                <participants group_id="P2" count="817"/>
                <participants group_id="P3" count="813"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="822"/>
                <participants group_id="P2" count="816"/>
                <participants group_id="P3" count="813"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="824"/>
                <participants group_id="P2" count="817"/>
                <participants group_id="P3" count="813"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="730"/>
                <participants group_id="P2" count="729"/>
                <participants group_id="P3" count="713"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Contraindications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Started Taking Glipizide</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved Out of Area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved Out of Country</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycemic Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized set included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Glimepiride</title>
          <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
        </group>
        <group group_id="B2">
          <title>TAK-875 25 mg</title>
          <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>TAK-875 50 mg</title>
          <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="824"/>
            <count group_id="B2" value="817"/>
            <count group_id="B3" value="813"/>
            <count group_id="B4" value="2454"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="9.56"/>
                    <measurement group_id="B2" value="56.8" spread="9.34"/>
                    <measurement group_id="B3" value="56.6" spread="9.81"/>
                    <measurement group_id="B4" value="56.9" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="637"/>
                    <measurement group_id="B2" value="646"/>
                    <measurement group_id="B3" value="648"/>
                    <measurement group_id="B4" value="1931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="362"/>
                    <measurement group_id="B4" value="1212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="451"/>
                    <measurement group_id="B4" value="1242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="651"/>
                    <measurement group_id="B2" value="641"/>
                    <measurement group_id="B3" value="637"/>
                    <measurement group_id="B4" value="1929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="617"/>
                    <measurement group_id="B2" value="598"/>
                    <measurement group_id="B3" value="601"/>
                    <measurement group_id="B4" value="1816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province Of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>For this outcome measure, number of participants evaluable were 823, 817 and 813 for each arm, respectively.</description>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.2" spread="10.66"/>
                    <measurement group_id="B2" value="166.2" spread="10.23"/>
                    <measurement group_id="B3" value="167.3" spread="10.19"/>
                    <measurement group_id="B4" value="166.6" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>For this outcome measure, number of participants evaluable were 822, 816 and 813 for each arm, respectively.</description>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.95" spread="18.415"/>
                    <measurement group_id="B2" value="87.35" spread="18.283"/>
                    <measurement group_id="B3" value="88.37" spread="18.796"/>
                    <measurement group_id="B4" value="87.55" spread="18.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>For this outcome measure, number of participants evaluable were 821, 816 and 813 for each arm, respectively.</description>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.34" spread="5.334"/>
                    <measurement group_id="B2" value="31.50" spread="5.253"/>
                    <measurement group_id="B3" value="31.43" spread="5.403"/>
                    <measurement group_id="B4" value="31.42" spread="5.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="533"/>
                    <measurement group_id="B3" value="502"/>
                    <measurement group_id="B4" value="1587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Glycosylated Hemoglobin (HbA1c) Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 8.5 percent (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="584"/>
                    <measurement group_id="B2" value="584"/>
                    <measurement group_id="B3" value="592"/>
                    <measurement group_id="B4" value="1760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <description>For this outcome measure, number of participants evaluable were 823, 817 and 812 for each arm, respectively.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.372" spread="5.293"/>
                    <measurement group_id="B2" value="6.566" spread="5.132"/>
                    <measurement group_id="B3" value="5.995" spread="4.711"/>
                    <measurement group_id="B4" value="6.312" spread="5.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Weeks 78 and 104</title>
        <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) to be collected at Weeks 78 and 104 relative to baseline.</description>
        <time_frame>Baseline and Weeks 78 and 104</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Weeks 78 and 104</title>
          <description>The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) to be collected at Weeks 78 and 104 relative to baseline.</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline assessment.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="0.814"/>
                    <measurement group_id="O2" value="8.01" spread="0.777"/>
                    <measurement group_id="O3" value="7.99" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.957"/>
                    <measurement group_id="O2" value="-0.82" spread="0.865"/>
                    <measurement group_id="O3" value="-0.98" spread="0.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as none of the participants had data for this arm at this time point.</measurement>
                    <measurement group_id="O2" value="-1.03" spread="1.159"/>
                    <measurement group_id="O3" value="0.03" spread="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hypoglycemia</title>
        <description>Participants were provided diaries to document any hypoglycemic events that occurred between study visits. Any experience of hypoglycemic signs and symptoms (regardless of the blood glucose value by glucometer) or had a blood glucose value less than or equal to (&lt;=) 70 milligram per deciliter (mg/dL) (3.9 millimole per liter (mmol/L) by glucometer (regardless of symptoms) were to be recorded.</description>
        <time_frame>Day 1 up to Weeks 78 and 104</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of double-blind study medication. Participants were analyzed according to the study medication they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hypoglycemia</title>
          <description>Participants were provided diaries to document any hypoglycemic events that occurred between study visits. Any experience of hypoglycemic signs and symptoms (regardless of the blood glucose value by glucometer) or had a blood glucose value less than or equal to (&lt;=) 70 milligram per deciliter (mg/dL) (3.9 millimole per liter (mmol/L) by glucometer (regardless of symptoms) were to be recorded.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of double-blind study medication. Participants were analyzed according to the study medication they received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="822"/>
                <count group_id="O2" value="816"/>
                <count group_id="O3" value="813"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 up to Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 up to Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 up to Week 78: Odds Ratios, corresponding confidence interval, and p-values were calculated using logistic regression with factors for treatment, country, schedule and baseline HbA1c value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 up to Week 78: Odds Ratios, corresponding confidence interval, and p-values were calculated using logistic regression with factors for treatment, country, schedule and baseline HbA1c value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 up to Week 104: Odds Ratios, corresponding confidence interval, and p-values were calculated using logistic regression with factors for treatment, country, schedule and baseline HbA1c value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1 up to Week 104: Odds Ratios, corresponding confidence interval, and p-values were calculated using logistic regression with factors for treatment, country, schedule and baseline HbA1c value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Weeks 78 and 104</title>
        <description>The change between the body weight to be collected at Weeks 78 and 104 relative to baseline.</description>
        <time_frame>Baseline and Weeks 78 and 104</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period. Data for body weight was not available at Week 104 due to early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Weeks 78 and 104</title>
          <description>The change between the body weight to be collected at Weeks 78 and 104 relative to baseline.</description>
          <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period. Data for body weight was not available at Week 104 due to early termination of the study.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.32" spread="0.981"/>
                    <measurement group_id="O2" value="84.55" spread="1.003"/>
                    <measurement group_id="O3" value="85.67" spread="0.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.492"/>
                    <measurement group_id="O2" value="-0.07" spread="0.524"/>
                    <measurement group_id="O3" value="-0.21" spread="0.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 78</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, schedule and visit-by-treatment interaction as fixed factors and with baseline value and baseline value by visit interaction as covariates.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.707</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.70</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 78</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>The testing procedure at 2-sided significance level of 0.025 was as follows: 1) TAK-875 25 mg vs. glimepiride, 2) TAK-875 50 mg plus metformin vs. glimepiride. If P-value was not greater than 0.025 at Step 1, then Step 2 was carried out.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, schedule and visit-by-treatment interaction as fixed factors and with baseline value and baseline value by visit interaction as covariates.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.678</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Weeks 26 and 52</title>
        <description>The change in the value of HbA1c collected at Weeks 26 and 52 relative to baseline.</description>
        <time_frame>Baseline and Weeks 26 and 52</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Weeks 26 and 52</title>
          <description>The change in the value of HbA1c collected at Weeks 26 and 52 relative to baseline.</description>
          <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="645"/>
                <count group_id="O3" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.039"/>
                    <measurement group_id="O2" value="-0.63" spread="0.039"/>
                    <measurement group_id="O3" value="-0.81" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.043"/>
                    <measurement group_id="O2" value="-0.65" spread="0.044"/>
                    <measurement group_id="O3" value="-0.81" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HbA1c &lt;7%</title>
        <time_frame>Weeks 26, 52, 78 and 104</time_frame>
        <population>FAS included all randomized subjects who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HbA1c &lt;7%</title>
          <population>FAS included all randomized subjects who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="645"/>
                <count group_id="O3" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="38.3"/>
                    <measurement group_id="O3" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as none of the participants had data for this arm at this time point.</measurement>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HbA1c &lt;7% for Participants Who Did Not Report Hypoglycemia</title>
        <time_frame>Weeks 26, 52, 78 and 104</time_frame>
        <population>Data for this outcome measure was not analyzed as prespecified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HbA1c &lt;7% for Participants Who Did Not Report Hypoglycemia</title>
          <population>Data for this outcome measure was not analyzed as prespecified in the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104</title>
        <description>The change between the fasting plasma glucose value to be collected at Weeks 26, 52, 78 and 104 relative to baseline.</description>
        <time_frame>Baseline and Weeks 26, 52, 78 and 104</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Glimepiride</title>
            <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
          </group>
          <group group_id="O2">
            <title>TAK-875 25 mg</title>
            <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TAK-875 50 mg</title>
            <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104</title>
          <description>The change between the fasting plasma glucose value to be collected at Weeks 26, 52, 78 and 104 relative to baseline.</description>
          <population>FAS included all randomized participants who received at least 1 dose of double-blind study medication and who had a baseline and at least 1 post- baseline value during the double-blind treatment period.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="816"/>
                <count group_id="O3" value="813"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.5" spread="41.25"/>
                    <measurement group_id="O2" value="165.2" spread="38.45"/>
                    <measurement group_id="O3" value="163.7" spread="38.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.5" spread="41.90"/>
                    <measurement group_id="O2" value="-17.4" spread="34.67"/>
                    <measurement group_id="O3" value="-23.0" spread="31.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="40.81"/>
                    <measurement group_id="O2" value="-19.3" spread="36.85"/>
                    <measurement group_id="O3" value="-23.7" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="41.87"/>
                    <measurement group_id="O2" value="-17.6" spread="30.03"/>
                    <measurement group_id="O3" value="-21.4" spread="41.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not reported as none of the participants had data for this arm at this time point.</measurement>
                    <measurement group_id="O2" value="-24.0" spread="1.41"/>
                    <measurement group_id="O3" value="-32.0" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events started after first dose of study drug and no more than 30 days for a serious adverse event after the last dose of study drug. Time of individual participant follow-up ranged from 1 to 735 days.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glimepiride</title>
          <description>TAK-875 placebo-matching tablets, orally, once daily and glimepiride 1 mg, over-encapsulated capsules, orally, once daily for 1 week followed by up-titration in 2 mg increments up to 6 mg, orally, once daily along with metformin greater than or equal to (&gt;=)1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks. Glimepiride dose could be down-titrated from 6 mg in case of recurrent or severe hypoglycemia.</description>
        </group>
        <group group_id="E2">
          <title>TAK-875 25 mg</title>
          <description>TAK-875 25 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
        <group group_id="E3">
          <title>TAK-875 50 mg</title>
          <description>TAK-875 50 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily along with metformin &gt;=1500 mg per day or maximum tolerated dose, tablets, orally for up to 104 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Intestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Keratitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Linitis plastica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="337" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="323" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="813"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="822"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="816"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="813"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

